Target Therapy and Immunotherapy For Gastric Cancer - Recent Updates

Abstract: Gastric cancer, with more than 1 million cases all over the globe, is a leading contributor to cancer mortality. In the recent past, the evolution of target therapies and the refining of already existing chemotherapy have widened the therapy choices for advanced gastric cancer and increased survival. In addition, more studies have been conducted all over the globe to extensively evaluate epigenomic and genomic heterogeneity of gastric cancer, leading to recognition of new sensitive and specific prognostic and predictive biomarkers and development of new molecular tumour classifications based on their molecular profiling. But, many clinical studies aimed at evaluating the efficiency of certain new molecular targets gave negative results. Hence, it is vital to further study the molecular features of subtypes of gastric carcinoma for the purpose of identifying new tools for selecting responsive tumor subtypes for future trials. The objective of this review is to give an overview of recent developments in the field of target therapy and immunotherapy in advanced gastric cancer.